Back to Newsroom
Back to Newsroom

ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm – CBMG, PRNB, MNTA, PTI

Tuesday, 25 August 2020 06:20 PM

Halper Sadeh LLP

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / August 25, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate:

Halper Sadeh LLP , Tuesday, August 25, 2020, Press release picture

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. Under the terms of the merger, Cellular Biomedicine stockholders (excluding certain parties) will receive $19.75 in cash for each outstanding share of common stock held immediately prior to the effective time of the merger. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/cellular-biomedicine-group-inc-cbmg-stock-merger/.

Principia Biopharma Inc. (NASDAQ:PRNB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sanofi for $100 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/principia-biopharma-inc-prnb-stock-merger-sanofi/.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Johnson & Johnson for $52.50 per share in cash. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/momenta-pharmaceuticals-inc-stock-merger-jnj.

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Yumanity Therapeutics. Under the terms of the merger agreement, Proteostasis will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of Proteostasis common stock, with existing Proteostasis shareholders expected to own approximately 32.5% of the combined company. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/proteostasis-therapeutics-inc-pti-yumanity-stock-merger/.

Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE: Halper Sadeh LLP

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: